Fortrea (FTRE) Expected to Post Quarterly Earnings on Thursday

Fortrea (NASDAQ:FTRE) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.2172 per share and revenue of $671.57 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Fortrea (NASDAQ:FTRE) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The company had revenue of $678.20 million during the quarter, compared to the consensus estimate of $647.57 million. Fortrea had a negative net margin of 3.18% and a positive return on equity of 10.72%. On average, analysts expect Fortrea to post $0.86 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Fortrea Price Performance

Shares of NASDAQ FTRE opened at $24.06 on Thursday. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -26.44, a PEG ratio of 0.55 and a beta of 1.93. The business has a 50-day moving average of $19.45 and a 200-day moving average of $16.72. The company has a debt-to-equity ratio of 1.98, a current ratio of 0.96 and a quick ratio of 0.96. Fortrea has a fifty-two week low of $8.55 and a fifty-two week high of $24.37.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. William Blair upgraded Fortrea to a “hold” rating in a report on Wednesday, July 29th. UBS Group increased their price target on Fortrea from $22.00 to $24.00 and gave the company a “neutral” rating in a research report on Tuesday. Barclays upgraded Fortrea from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $22.00 to $23.00 in a research note on Tuesday, October 6th. Robert W. Baird set a $23.00 price target on Fortrea in a research report on Thursday, July 30th. Finally, Wall Street Zen raised Fortrea from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $22.80.

Insider Transactions at Fortrea

In other Fortrea news, CEO Anshul Thakral sold 99,869 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $19.16, for a total value of $1,913,490.04. Following the completion of the sale, the chief executive officer owned 316,797 shares in the company, valued at $6,069,830.52. This trade represents a 23.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.73% of the company’s stock.

Fortrea Company Profile

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.